TheraRadar
Clinical-Stage Companies / Laboratorios Leti, S.L.

Laboratorios Leti, S.L.

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 11/1/2015

21
Total Trials
3
Phase 3
18
Phase 2
0
Recruiting
189
Score

Pipeline by Phase

Phase 3
3
Phase 2
18
Phase 1

Therapeutic Focus

Rhinoconjunctivitis Allergic Asthma Rhinitis Allergic Rhinitis Allergy to Grass Pollen

Clinical Trials (21)

NCT00831025 Phase 3 COMPLETED

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen

Started: 1/1/2008

NCT00916422 Phase 3 COMPLETED

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen

Started: 6/1/2008

NCT00916760 Phase 3 COMPLETED

Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica

Started: 2/1/2008

NCT00622362 Phase 2 TERMINATED

Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract

Started: 1/1/2008

NCT02340130 Phase 2 COMPLETED

Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma

Started: 9/1/2014

NCT01821716 Phase 2 COMPLETED

Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract

Started: 3/1/2013

NCT01591343 Phase 2 TERMINATED

Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma

Started: 6/1/2012

NCT01739322 Phase 2 COMPLETED

Biological Standardization of Platanus Acerifolia Allergen Extract

Started: 11/1/2012

NCT02512653 Phase 2 COMPLETED

Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)

Started: 11/1/2015

NCT01984541 Phase 2 COMPLETED

To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.

Started: 3/1/2014

NCT01984528 Phase 2 COMPLETED

To Determine the Minimum Amount of Alternaria Alternata Allergen Extract Producing a Positive Skin Reaction.

Started: 2/1/2014

NCT01675349 Phase 2 COMPLETED

Biological Standardization of Chenopodium Album Allergen Extract

Started: 11/1/2012

NCT01740024 Phase 2 COMPLETED

Biological Potency of the Cat Epithelial Allergenic Extracts

Started: 11/1/2012

NCT01734265 Phase 2 COMPLETED

Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

Started: 11/1/2012

NCT01597752 Phase 2 COMPLETED

Biological Standardization of Blomia Tropicalis Allergen Extract

Started: 4/1/2012

NCT01394289 Phase 2 COMPLETED

Biological Standardization of Lolium Perenne Allergen Extract

Started: 9/1/2011

NCT01430117 Phase 2 COMPLETED

Biological Standardization of Poa Pratensis Allergen Extract

Started: 10/1/2011

NCT01407835 Phase 2 COMPLETED

Biological Standardization of Dactylis Glomerata Allergen Extract

Started: 10/1/2011

NCT01408238 Phase 2 COMPLETED

Biological Standardization of Secale Cereale Allergen Extract

Started: 10/1/2011

NCT00917488 Phase 2 COMPLETED

Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).

Started: 5/1/2009

NCT00718744 Phase 2 COMPLETED

Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units

Started: 6/1/2008

Drug Candidates

DEPIGOID Dermatophagoides pteronyssinus Polymerized TOL of Dermatophagoides pteronyssinus Placebo Comparator DP/MG/14-1 DP/MG/14-2 Immunotherapy with modified extract of Olea europaea pollen Placebo Prick test Dermatophagoides pteronyssinus allergen extract Depigoid® (500 DPP/ml) Prick test Platanus acerifolia allergen extract
Activity Status: Inactive
Last Trial Started: 11/1/2015
Last Trial Ended: 6/1/2018
Trials (12 months): 0
Completed Trials: 19
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.